GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Forward PE Ratio

Vertex Pharmaceuticals (BSP:VRTX34) Forward PE Ratio : 24.39 (As of Apr. 29, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Forward PE Ratio?

Vertex Pharmaceuticals's Forward PE Ratio for today is 24.39.

Vertex Pharmaceuticals's PE Ratio without NRI for today is 25.00.

Vertex Pharmaceuticals's PE Ratio for today is 28.62.


Vertex Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Vertex Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Forward PE Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend 2019-12 2020-12 2021-12 2022-12 2023-12 2024-04
Forward PE Ratio
8.33 20.79 16.95 18.28 24.88 24.21

Vertex Pharmaceuticals Quarterly Data
2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 10.54 6.73 8.33 7.51 8.50 5.72 20.79 18.80 17.15 14.39 16.95 17.36 20.41 18.69 18.28 22.22 24.88 22.12 24.88 25.77

Competitive Comparison of Vertex Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Vertex Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Forward PE Ratio falls into.



Vertex Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Vertex Pharmaceuticals  (BSP:VRTX34) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Vertex Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines